Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Tóm tắt
Từ khóa
Tài liệu tham khảo
PhRMA: medicines in development for infectious diseases. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2007.
Theravance announces positive results from phase 2 clinical study with investigational antibiotic in patients with complicated skin and skin structure infections: TD-1792 achieves primary endpoint. South San Francisco, CA: Theravance, 2007.
FDA issues approvable letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic. 18 March 2008 ed. Basel, Switzerland: Basilea Pharmaceutica, 2008.
Theravance receives additional information regarding FDA cancellation of Advisory Committee Meeting. South San Francisco, CA: Theravance, 2008.
Food and Drug Administration. Advisory Committee Calendar. Available at: http://www.fda.gov/oc/advisory/accalendar/2008/2008ACcalendar.html#November. Accessed 13 November 2008.
United States Food and Drug Administration. Doripenem. Available at: http://www.fda.gov/cder/rdmt/InternetNME07.htm. Accessed 13 November 2008.
JS Solomkin, O Umeh, J Jiang, et al. Doripenem vs. meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections [abstract L-487]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Johnson & Johnson. FDA requires additional information on DORIBAX for treatment of hospital-acquired pneumonia. Langhorne, PA: Johnson & Johnson, 2008.
PTK 0796 completed a randomized, evaluator200 patient phase 2 complicated skin and skin structure infection (cSSSI) clinical study with IV and oral step-down therapy compared to Zyvox. Boston: Paratek, 2007.
Macone A, Donatelli J, Dumont T, Levy S, Tanaka S. In-vitro activity of PTK0796 against gram-positive and gram-negative organisms. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2003.
Traczewski M, Brown S. PTK0796: in vitro potency and spectrum of activity compared to ten other antimicrobial compounds. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2003.
Sahm D, Draghi D, Thornsberry C. Activity of ME1036, a novel anti-MRSA carbapenem, against gram-positive and gram-negative pathogens. In: Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society of Microbiology, 2006.
Kurazono M, Hirai Y, Takahata S, etal Efficacy of ME1036 against Enterobacteriaceae harboring a variety of beta-lactamases including ESBLs [abstract F-331]. In: Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 2004:197.
Brown SD, Traczewski MM. ME1036: in vitro potency and spectrum of activity [abstract F1-342]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Pace J, Stevens T, Hamrick J, Hoban D, Bouchillon S, Xerri L. PZ-601 susceptibility of gram-positive pathogens causative for systemic and respiratory infections [abstract F1-230]. In: Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society of Microbiology, 2006.
Pace J, Stevens T, Hoban D, etal PZ-601 susceptibility of important gram-negative bacterial species causative for community-acquired pneumonia (CAP), complicated skin and skin structure infections (cSSSI), and intra-abdominal infections (IAI) [abstract F1-229]. In: Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society of Microbiology, 2006.
Protez pharmaceuticals to be acquired by Novartis. Malvern, PA: Protez Pharmaceuticals, 2008.
Page M, Desarbre E, Geier C, Hofer B. Activity of BAL30376 against gram-negative bacteria [abstract F1-229]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Bowker K, Noel AR, MacGowan A, Walsh TR. In vitro potency of BAL30376 against gram-negative bacilli (GNB) [abstract F1-313]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Schmitt-Hoffmann A, Gebhardt K, Gaucher B, Desarbre E, Page M. Efficacy of BAL30376 in a murine model of gram-negative sepsis [abstract F1-315]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Ishii Y, Sugihara S, Tateda K, Yamaguchi K. In vitro synergistic effects of combinations of CP3242, as a novel metallo-beta-lactamase inhibitor, and carbapenems against carbapenemase producing organisms [abstract F1-331]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Osaki Y, Morinaka A, Mikuniya K, etal CP3242, a novel metallo-beta-lactamase inhibitor: in vitro and in vivo efficacy against clinically isolated metallo-beta-lactamase-producing P. aeruginosa [abstract F1-332]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Muto Y, Matsumoto K, Morinaka A, etal CP3242, a novel metallo-beta-lactamase inhibitor: pharmacokinetics and in vivo pharmacodynamic activities against metallo-beta-lactamase-producing P. aeruginosa in a murine thigh infection model [abstract F1-333]. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Maroko R, Cooper A, Dukart G, Dartois N, Gandjini H. Results of phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/cilastatin (IMI) regimen in treatment of patients (Pts) with hospital-acquired pneumonia (HAP). In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society of Microbiology, 2007.
Lin YC, 2006, J Microbiol Immunol Infect, 39, 67
GlaxoSmithKline and Mpex Pharmaceuticals form alliance to develop novel efflux pump inhibitors for use against serious gram-negative infections. London, and San Diego: GlaxoSmithKline, 2008.
Novexel and Forest Laboratories announce license agreement for NXL104, a novel broad-spectrum beta lactamase inhibitor. Paris: Novexel, 2008.
FDA guidance documents. Rockville, MD: US Food and Drug Administration, 2008. Available at: http://www.fda.gov/cder/guidance/. Accessed 13 November 2008.
Clinical trial design for community-acquired pneumonia: public workshop, January 17-18, 2008. Rockville, MD: US Food and Drug Administration, 2008. Available at: http://www.fda.gov/CDER/meeting/CAP/presentations.htm. Accessed 13 November 2008.
Wellcome Trust and GlaxoSmithKline announce partnership to target drug-resistant hospital infections. Oxford, UK: Wellcome Trust, 2007.